Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Garcia Gomez, Antonio ^a,b,c   Ocio, Enrique M ^a,c   Crusoe, Edvan ^a,c   Santamaria, Carlos ^b   Hernández Campo, Pilar ^b   Blanco, Juan F ^c   Sanchez Guijo, Fermin M ^b,c   Hernández Iglesias, Teresa ^a   Briñón, Jesús G ^d   Fisac Herrero, Rosa M ^e   Lee, Francis Y ^f   Pandiella, Atanasio ^a,c   San Miguel, Jesús F ^a,b,c   Garayoa, Mercedes ^a,b,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b ISCIII)   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e HOSPITAL GENERAL DE SEGOVIA   (Spain)

^f BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN K; CHEMOKINE RECEPTOR CCR1; DASATINIB; F ACTIN; NUCLEAR FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TELOMERASE REVERSE TRANSCRIPTASE; VITRONECTIN RECEPTOR; WNT PROTEIN; ANABOLIC AGENT; CSK TYROSINE PROTEIN KINASE; CSK TYROSINE-PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; SNF1 RELATED PROTEIN KINASES; SNF1-RELATED PROTEIN KINASES; STEM CELL FACTOR RECEPTOR; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR NFAT;

ANABOLIC EFFECT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIRESORPTIVE EFFECT; ARTICLE; BONE METABOLISM; BONE MINERALIZATION; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXTRACELLULAR MATRIX; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MESENCHYMAL STEM CELL; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRABECULAR BONE; ANIMAL; BONE REMODELING; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; MONONUCLEAR CELL; OSTEOLYSIS; PATHOLOGY; PHOSPHORYLATION; WNT SIGNALING PATHWAY;

ANABOLIC AGENTS; ANIMALS; BONE REMODELING; BONE RESORPTION; CATHEPSIN K; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LEUKOCYTES, MONONUCLEAR; MESENCHYMAL STEM CELLS; MICE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; THIAZOLES; WNT SIGNALING PATHWAY;

EID: 84859964339     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034914     Document Type: Article

References (72)

1. Rachner TD, Khosla S, Hofbauer LC, (2011) Osteoporosis: now and the future. Lancet 377: 1276-1287.
2. Vallet S, Smith MR, Raje N, (2010) Novel bone-targeted strategies in oncology. Clin Cancer Res 16: 4084-4093.
3. Weilbaecher KN, Guise TA, McCauley LK, (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11: 411-425.
4. Basak GW, Srivastava AS, Malhotra R, Carrier E, (2009) Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 10: 345-346.
5. Yaccoby S, (2010) Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 149: 311-321.
6. Fowler JA, Edwards CM, Croucher PI, (2011) Tumor-host cell interactions in the bone disease of myeloma. Bone 48: 121-128.
7. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, et al. (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088.
8. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, et al. (2010) Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol 38: 141-153.
9. Capdeville R, Buchdunger E, Zimmermann J, Matter A, (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
10. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
11. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, et al. (2008) Long-term imatinib therapy promotes bone formation in CML patients. Blood 111: 2538-2547.
12. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC, (2010) Dysregulation of bone remodeling by imatinib mesylate. Blood 115: 766-774.
13. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, et al. (2007) Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 22: 1679-1689.
14. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, et al. (2006) Imatinib as a potential antiresorptive therapy for bone disease. Blood 107: 4334-4337.
15. Olivieri A, Manzione L, (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18 (Suppl 6): vi42-46.
16. Aguilera DG, Tsimberidou AM, (2009) Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 5: 281-289.
17. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, et al. (2009) Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23: 994-997.
18. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ, (2009) Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23: 590-594.
19. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, et al. (2010) Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29: 3196-3207.
20. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, et al. (2010) The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. BMC Cancer 10: 298.
21. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, et al. (2011) Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematol Oncol.
22. Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, et al. (2010) Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro. Leukemia 24: 1357-1359.
23. Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, et al. (2003) Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 120: 846-849.
24. Wang L, Zhao G, Olivares-Navarrete R, Bell BF, Wieland M, et al. (2006) Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to 1,25-dihydroxy vitamin D3. Biomaterials 27: 3716-3725.
25. Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, et al. (2009) Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23: 1515-1527.
26. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
27. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, et al. (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66: 5781-5789.
28. Gregory CA, Gunn WG, Peister A, Prockop DJ, (2004) An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 329: 77-84.
29. Xiao G, Jiang D, Ge C, Zhao Z, Lai Y, et al. (2005) Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem 280: 30689-30696.
30. Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R, (2004) Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med 2: 6.
31. Chaudhary LR, Hofmeister AM, Hruska KA, (2004) Differential growth factor control of bone formation through osteoprogenitor differentiation. Bone 34: 402-411.
32. Hock JM, Canalis E, (1994) Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 134: 1423-1428.
33. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, et al. (2008) PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res 23: 1519-1528.
34. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, et al. (2000) Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151: 311-320.
35. Veracini L, Franco M, Boureux A, Simon V, Roche S, et al. (2005) Two functionally distinct pools of Src kinases for PDGF receptor signalling. Biochem Soc Trans 33: 1313-1315.
36. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044.
37. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M, (2005) Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308: 1472-1477.
38. Wang X, Goh CH, Li B, (2007) p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix. Endocrinology 148: 1629-1637.
39. Choi YH, Gu YM, Oh JW, Lee KY, (2011) Osterix is regulated by Erk1/2 during osteoblast differentiation. Biochem Biophys Res Commun 415: 472-478.
40. Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, et al. (2007) Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. BMC Genomics 8: 70.
41. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
42. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, et al. (2009) Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 113: 4319-4330.
43. Vaananen HK, Laitala-Leinonen T, (2008) Osteoclast lineage and function. Arch Biochem Biophys 473: 132-138.
44. Teitelbaum SL, (2000) Bone resorption by osteoclasts. Science 289: 1504-1508.
45. Asagiri M, Takayanagi H, (2007) The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
46. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
47. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, et al. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741-745.
48. Takayanagi H, (2007) The role of NFAT in osteoclast formation. Ann N Y Acad Sci 1116: 227-237.
49. Martinez-Martinez S, Rodriguez A, Lopez-Maderuelo MD, Ortega-Perez I, Vazquez J, et al. (2006) Blockade of NFAT activation by the second calcineurin binding site. J Biol Chem 281: 6227-6235.
50. Nakamura I, Duong le T, Rodan SB, Rodan GA, (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25: 337-344.
51. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, et al. (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97: 3349-3353.
52. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, et al. (2003) Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101: 3568-3573.
53. Roodman GD, Dougall WC, (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34: 92-101.
54. Charbord P, (2010) Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 21: 1045-1056.
55. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147.
56. Kagami H, Agata H, Tojo A, (2011) Bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for bone tissue engineering: basic science to clinical translation. Int J Biochem Cell Biol 43: 286-289.
57. Khosla S, Westendorf JJ, Modder UI, (2010) Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 28: 2124-2128.
58. Nandi SK, Roy S, Mukherjee P, Kundu B, De DK, et al. (2010) Orthopaedic applications of bone graft & graft substitutes: a review. Indian J Med Res 132: 15-30.
59. Mazo M, Gavira JJ, Abizanda G, Moreno C, Ecay M, et al. (2010) Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat. Cell Transplant 19: 313-328.
60. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, et al. (2006) Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12: 7180-7186.
61. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, et al. (2010) The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo. J Bone Miner Res 25: 1759-1770.
62. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, et al. (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 36: 1357-1364.
63. Sambrook P, Cooper C, (2006) Osteoporosis. Lancet 367: 2010-2018.
64. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, et al. (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97: 964-970.
65. Roodman GD, (2009) Pathogenesis of myeloma bone disease. Leukemia 23: 435-441.
66. Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, et al. (2007) Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 48: 2032-2041.
67. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM, (2001) Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91: 1219-1230.
68. Yaccoby S, (2010) Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 51: 213-220.
69. Giuliani N, Rizzoli V, Roodman GD, (2006) Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 108: 3992-3996.
70. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, et al. (2008) Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112: 1346-1356.
71. Rosen LS, (2004) New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Oncology (Williston Park) 18: 26-32.
72. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, et al. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20: 1303-1317.